Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors. 2010

Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06330 Ankara, Turkey. gokcene@gazi.edu.tr

Three novel series of diaryl heterocyclic derivatives bearing the 2-oxo-5H-furan, 2-oxo-3H-1,3-oxazole, and 1H-pyrazole moieties as the central heterocyclic ring were synthesized and their in vitro inhibitory activities on COX-1 and COX-2 isoforms were evaluated using a purified enzyme assay. The 2-oxo-5H-furan derivative 6b was identified as potent COX inhibitor with selectivity toward COX-1 (COX-1 IC(50)=0.061 microM and COX-2 IC(50)=0.325 microM; selectivity index (SI)=0.19). Among the 1H-pyrazole derivatives, 11b was found to be a potent COX-2 inhibitor, about 38 times more potent than Rofecoxib (COX-2 IC(50)=0.011 microM and 0.398 microM, respectively), but showed no selectivity for COX-2 isoform. Compound 11c demonstrated strong and selective COX-2 inhibitory activity (COX-1 IC(50)=1 microM, COX-2 IC(50)=0.011 microM; SI= approximately 92). Molecular docking studies of compounds 6b and 11b-d into the binding sites of COX-1 and COX-2 allowed to shed light on the binding mode of these novel COX inhibitors.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D052246 Cyclooxygenase 2 Inhibitors A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2. COX-2 Inhibitor,COX2 Inhibitor,Coxib,Cyclooxygenase 2 Inhibitor,Cyclooxygenase-2 Inhibitor,COX-2 Inhibitors,COX2 Inhibitors,Coxibs,Cyclooxygenase-2 Inhibitors,2 Inhibitor, Cyclooxygenase,COX 2 Inhibitor,COX 2 Inhibitors,Inhibitor, COX-2,Inhibitor, COX2,Inhibitor, Cyclooxygenase 2,Inhibitor, Cyclooxygenase-2,Inhibitors, COX-2,Inhibitors, COX2,Inhibitors, Cyclooxygenase 2,Inhibitors, Cyclooxygenase-2

Related Publications

Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
January 2017, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
March 2021, Archiv der Pharmazie,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
November 2012, European journal of medicinal chemistry,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
March 2011, Bioorganic & medicinal chemistry letters,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
January 2024, Archiv der Pharmazie,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
January 2024, Journal of biomolecular structure & dynamics,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
April 2006, Bioorganic & medicinal chemistry,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
January 2018, Iranian journal of pharmaceutical research : IJPR,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
April 2017, Bioorganic & medicinal chemistry letters,
Gökçen Eren, and Serdar Unlü, and Maria-Teresa Nuñez, and Luis Labeaga, and Francisco Ledo, and Antonio Entrena, and Erden Banoğlu, and Gabriele Costantino, and M Fethi Sahin
August 2023, Chemico-biological interactions,
Copied contents to your clipboard!